Bacterial and opportunistic infections during anti-TNF therapy

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 6, 2006, Pages 1181-1195

  Strangfeld, Anja ^b   Listing, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

infections; rheumatic diseases; risk evaluation; TNF antagonists

Indexed keywords

ADALIMUMAB; AMPICILLIN; ANTIBIOTIC AGENT; AZATHIOPRINE; BCG VACCINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; BACTERIAL INFECTION; BONE INFECTION; CLINICAL RESEARCH; CLINICAL TRIAL; COCCIDIA; COCCIDIOIDOMYCOSIS; DISEASE SEVERITY; DRUG WITHDRAWAL; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HOST RESISTANCE; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; INFECTIOUS ARTHRITIS; LISTERIA MONOCYTOGENES; LISTERIOSIS; LOWER RESPIRATORY TRACT INFECTION; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; TUBERCULOSIS; URINARY TRACT INFECTION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; IMMUNOLOGY; RISK FACTOR;

ANTIRHEUMATIC AGENTS; BACTERIAL INFECTIONS; HUMANS; OPPORTUNISTIC INFECTIONS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751165258     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.08.010     Document Type: Review

References (78)

1. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis and Rheumatism 37 4 (1994 Apr) 481-494
2. Thomas E., Symmons D.P., Brewster D.H., et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. The Journal of Rheumatology 30 5 (2003 May) 958-965
3. Sihvonen S., Korpela M., Laippala P., et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scandinavian Journal of Rheumatology 33 4 (2004) 221-227
4. Doran M.F., Pond G.R., Crowson C.S., et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year-period. Arthritis and Rheumatism 46 (2002) 625-631
5. Stuck A.E., Minder C.E., and Frey F.J. Risk of Infectious Complications in Patients Taking Glucocorticosteroids. Reviews of Infectious Diseases 11 6 (1989 Nov) 954-963
6. Gluck T., Kiefmann B., Grohmann M., et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. The Journal of Rheumatology 32 8 (2005 Aug) 1473-1480
7. Boerbooms A.M., Kerstens P.J., van Loenhout J.W., et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 24 6 (1995 Jun) 411-421
8. Cunnane G., Doran M., and Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Practice and Research Clinical Rheumatology 17 2 (2003 Apr) 345-363
9. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study. Arthritis and Rheumatism 46 9 (2002 Sep) 2287-2293
10. Zochling J., Bohl-Buhler M.H., Baraliakos X., et al. The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clinical Rheumatology 25 5 (2006 Sep) 648-658
11. Braun J., Bollow M., Remlinger G., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism 41 (1998) 58-67
12. Martinez A., Pacheco-Tena C., Vazquez-Mellado J., and Burgos-Vargas R. Relationship between disease activity and infection in patients with spondyloarthropathies. Annals of the Rheumatic Diseases 63 10 (2004 Oct) 1338-1340
13. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and Rheumatism 52 11 (2005 Oct 27) 3403-3412
14. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 19 (2006 May 17) 2275-2285
15. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 50 11 (2004 Nov) 3432-3443
16. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk - A multicenter active-surveillance report. Arthritis and Rheumatism 48 8 (2003 Aug) 2122-2127
17. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 54 7 (2006 Jun 26) 2136-2146
18. Davis J.C., van der Heijde D.M., Braun J., et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Annals of the Rheumatic Diseases 64 11 (2005 Nov) 1557-1562
19. Alarcon G.S. Methotrexate use in rheumatoid arthritis. A Clinician's perspective. Immunopharmacology 47 2-3 (2000 May) 259-271
20. Furst D.E., Breedveld F.C., Burmester G.R., et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Annals of the Rheumatic Diseases 59 supplement 1 (2000 Nov) i1-i2
21. Silman A., Klareskog L., Breedveld F., et al. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Annals of the Rheumatic Diseases 59 6 (2000 Jun) 419-420
22. Silman A., Symmons D., Scott D.G., and Griffiths I. British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases 62 supplement 2 (2003 Nov) ii28-ii29
23. Askling J., Fored C.M., Geborek P., et al. Swedish registers to examine drug safety and clinical issues in RA. Annals of the Rheumatic Diseases 65 6 (2006 Jun) 707-712
24. Zink A., Listing J., Kary S., et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Annals of the Rheumatic Diseases 64 9 (2005 Sep) 1274-1279
25. Hetland M.L., Unkerskov J., Ravn T., et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scandinavian Journal of Rheumatology 34 1 (2005) 40-44
26. Saunders B.M., Tran S., Ruuls S., et al. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. Journal of Immunology 174 8 (2005 Apr 15) 4852-4859
27. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14 (1996) 397-440
28. Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism 38 4 (1995 Apr) 499-505
29. Camussi G., Albano E., Tetta C., and Bussolino F. The molecular action of tumor necrosis factor-alpha. European Journal of Biochemistry 202 1 (1991 Nov 15) 3-14
30. Flynn J.L., Goldstein M.M., Chan J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 6 (1995 Jun) 561-572
31. Mohan V.P., Scanga C.A., Yu K., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infection and Immunity 69 3 (2001 Mar) 1847-1855
32. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism 54 8 (2006 Jul 25) 2368-2376
33. Kroesen S., Widmer A.F., Tyndall A., and Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42 5 (2003 May) 617-621
34. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis and Rheumatism 54 2 (2006 Feb) 628-634
35. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism 52 2 (2005 Feb) 582-591
36. Davis Jr. J.C., van der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis and Rheumatism 48 11 (2003 Nov) 3230-3236
37. Khanna D., McMahon M., and Furst D.E. Safety of tumour necrosis factor-alpha antagonists. Drug Safety 27 5 (2004) 307-324
38. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England Journal of Medicine 345 15 (2001 Oct 11) 1098-1104
39. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Infectious Diseases 3 3 (2003 Mar) 148-155
40. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical Infectious Diseases 38 9 (2004 May 1) 1261-1265
41. Wallis R.S., Broder M., Wong J., and Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clinical Infectious Diseases 39 8 (2004 Oct 15) 1254-1255
42. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clinical Infectious Diseases 41 supplement 3 (2005 Aug 1) S199-S203
43. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety. Annals of the Rheumatic Diseases 63 12 (2004 Dec) 1538-1543
44. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis and Rheumatism 52 6 (2005 Jun) 1766-1772
45. Deepe Jr. G.S. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clinical Infectious Diseases 41 supplement 3 (2005 Aug 1) S204-S207
46. Lee J.H., Slifman N.R., Gershon S.K., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis and Rheumatism 46 10 (2002 Oct) 2565-2570
47. Slifman N.R., Gershon S.K., Lee J.H., et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis and Rheumatism 48 2 (2003 Feb) 319-324
48. Filler S.G., Yeaman M.R., and Sheppard D.C. Tumor necrosis factor inhibition and invasive fungal infections. Clinical Infectious Diseases 41 supplement 3 (2005 Aug 1) S208-S212
49. Seddik M., Melliez H., Seguy D., et al. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflammatory Bowel Diseases 11 6 (2005 Jun) 618-620
50. De Rosa F.G., Shaz D., Campagna A.C., et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?. Infection Control and Hospital Epidemiology 24 7 (2003 Jul) 477-482
51. Allendoerfer R., and Deepe Jr. G.S. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. Journal of Immunology 160 12 (1998 Jun 15) 6072-6082
52. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis and Rheumatism 50 6 (2004 Jun) 1959-1966
53. CDC. FoodNet Surveillance Report for 2004 (Final Report). Atlanta; 2006 Jun. http://www.cdc.gov/foodnet/annual/2004/Report.pdf. Last access July 2006.
54. Hinshaw L.B., Emerson Jr. T.E., Taylor Jr. F.B., et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. The Journal of Trauma 33 4 (1992 Oct) 568-573
55. Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273 12 (1995 Mar 22) 934-941
56. Cohen J., and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine 24 9 (1996 Sep) 1431-1440
57. Abraham E., Glauser M.P., Butler T., et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277 19 (1997 May 21) 1531-1538
58. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Medicine 25 6 (1999 Jun) 556-566
59. Fisher Jr. C.J., Agosti J.M., Opal S.M., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. The New England Journal of Medicine 334 26 (1996 Jun 27) 1697-1702
60. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 29 7 (2001 Jul) 1303-1310
61. Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism 50 4 (2004 Apr) 1051-1065
62. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 9410 (2004 Feb 28) 675-681
63. Moreland L.W., Cohen S.B., Baumgartner S.W., et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. The Journal of Rheumatology 28 6 (2001 Jun) 1238-1244
64. Kling A., Mjorndal T., and Rantapaa-Dahlqvist S. Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNF alpha antagonists. Jcr-Journal of Clinical Rheumatology 10 3 (2004 Jun) 119-122
65. Antoni C.E., Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis and Rheumatism 52 4 (2005 Apr) 1227-1236
66. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 52 10 (2005 Oct) 3279-3289
67. Baghai M., Osmon D.R., Wolk D.M., et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clinic Proceedings 76 6 (2001 Jun) 653-656
68. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis and Rheumatism 48 11 (2003 Nov) 3013-3022
69. Butler J.C., Breiman R.F., Campbell J.F., et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270 15 (1993 Oct 20) 1826-1831
70. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and Rheumatism 46 6 (2002 Jun) 1443-1450
71. Vestergaard C., Johansen C., Otkjaer K., et al. Tumor necrosis factor-alpha-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB. Cytokine 29 2 (2005 Jan 21) 49-55
72. Foxman B., and Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infectious Disease Clinics of North America 17 2 (2003 Jun) 227-241
73. Zink A., Strangfeld A., Schneider M., et al. Effectiveness of TNF inhibitors in rheumatoid arthritis in an observational cohort study - comparison of patients according to their eligibility for major randomised clinical trials. Arthritis and Rheumatism 54 11 (2006 Nov) 3399-3407
74. Nicolle L.E. Asymptomatic bacteriuria: when to screen and when to treat. Infectious Disease Clinics of North America 17 2 (2003 Jun) 367-394
75. Sipsas N.V., Papaparaskevas J., Stefanou I., et al. Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. Diagnostic Microbiology and Infectious Disease 55 4 (2006 Aug) 343-345
76. Netea M.G., Radstake T., Joosten L.A., et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis and Rheumatism 48 7 (2003 Jul) 1853-1857
77. Wilson M.G., Kelley K., and Thornhill T.S. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. The Journal of Bone and Joint Surgery. American Volume 72 6 (1990 Jul) 878-883
78. Giles J.T., Bartlett S.J., Gelber A.C., et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis and Rheumatism 55 2 (2006 Apr 15) 333-337